

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)



(10) International Publication Number
WO 2021/214117 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) G01N 33/68 (2006.01)
A61K 31/506 (2006.01) A61P 35/00 (2006.01)
C07D 333/46 (2006.01)

(21) International Application Number:

PCT/EP2021/060338

(22) International Filing Date:

21 April 2021 (21.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20170641.3 21 April 2020 (21.04.2020) EP

(71) Applicant: **IOMX THERAPEUTICS AG** [DE/DE];
Fraunhoferstrasse 13, 82152 Martinsried (DE).

(72) Inventors: **SENNHENN, Peter**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **BISSINGER, Stefan**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **LOFERER, Hannes**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **BANCROFT, David**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **MICHELS, Tillmann**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **KHANDELWAL, Nisit**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE).

(74) Agent: **KUTTENKEULER, David**; Boehmert & Boehmert Anwaltspartnerschaft mbB, Pettenkoferstrasse 22, 80336 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF

(57) Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (*inter-alia*) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

WO 2021/214117 A1